Strošek In Učinkovitost Zdravljenja Shizofrenije Z Atipičnimi Antipsihotiki V Sloveniji: Raziskava Stroškovne Učinkovitosti / The Cost And Effects Of Atypical Antipsychotic Agents In Patients With Schizophrenia In Slovenia: A Cost Effectiveness Study

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4nd ed.), text revision (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000.Search in Google Scholar

2. Murray CJL, Lopez AD. The global burden of disease. Cambridge: Harvard University Press, 1996.Search in Google Scholar

3. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: The National Comorbidity Survey. Arch Gen Psychiatry 1996; 53: 1022-1031.10.1001/archpsyc.1996.01830110060007Search in Google Scholar

4. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002; 47: 833-843.10.1177/070674370204700904Search in Google Scholar

5. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349.10.1176/appi.ajp.161.8.1334Search in Google Scholar

6. Picchioni MM, Murray RM. Schizophrenia. BMJ 2007; 335: 91-95.10.1136/bmj.39227.616447.BESearch in Google Scholar

7. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21: 567-577.10.1093/schbul/21.4.567Search in Google Scholar

8. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.10.1016/S0140-6736(08)61764-XSearch in Google Scholar

9. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry 2000; 157: 514-520.10.1176/appi.ajp.157.4.51410739409Search in Google Scholar

10. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. Schizophrenia Patient Outcomes Research Team (PORT): the 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71-93.10.1093/schbul/sbp116280014419955390Search in Google Scholar

11. Inštitut za varovanje zdravja Republike Slovenije. Ambulantno predpisovanje zdravil v Sloveniji po ATC Klasifikaciji v letu 2009. Pridobljeno 28.1.2012 s spletne strani: http://www.ivz.si.Search in Google Scholar

12. IMS health. Pridobljeno 30.1.2012 s spletne strani: http://www.IMShealth.com.Search in Google Scholar

13. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 2004; 21: 419-429.Search in Google Scholar

14. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, Damaraju CV, Kalali AH, Mahmoud R. Randomized, double-blind, placebo-controlled study of paliperidoneextended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009; 166: 691-701.10.1176/appi.ajp.2009.0804061319411369Search in Google Scholar

15. Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extendedrelease for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009; 113: 56-64.10.1016/j.schres.2009.05.02119560322Search in Google Scholar

16. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007; 90:147-161.10.1016/j.schres.2006.09.01217092691Search in Google Scholar

17. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito GG, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690.10.1001/archpsyc.60.7.681Search in Google Scholar

18. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D. Efficacy and tolerability of once-daily extended release quetiapinefumarate in acute schizophrenia: a randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2007; 68: 832-842.10.4088/JCP.v68n0603Search in Google Scholar

19. Arvanitis LA, Miller BG. Multiple fixed doses of „Seroquel“ (quetiapine) in patients with acute exacerbation of schizophrenia:a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-246.10.1016/S0006-3223(97)00190-XSearch in Google Scholar

20. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidoneextended-release tablets: a 6-week placebocontrolled trial. Schizophr Res 2007; 90: 147-161.10.1016/j.schres.2006.09.012Search in Google Scholar

21. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, HsiaoJK. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators: effectiveness of antipsychotic drugs in patientswith chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.10.1056/NEJMoa05168816172203Search in Google Scholar

22. Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J,Caro O, Leadbetter J, Assuncao S. Response and relapse inpatients with schizophrenia treated with olanzapine, risperidone,quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (ICSOHO) study. J Clin Psychiatry 2005; 66: 1021-1030.10.4088/JCP.v66n081016086618Search in Google Scholar

23. Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res 2008; 98: 8-15.10.1016/j.schres.2007.04.03517596914Search in Google Scholar

24. Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1023.10.1056/NEJMoa051688Search in Google Scholar

25. IMS health. Pridobljeno 30.1.2012 s spletne strani: http://www. IMShealth.com.Search in Google Scholar

26. Zavod za zdravstveno zavarovanje Slovenije. Cene storitev v zdravstvu od 1.1. 2012 dalje. Pridobljeno 25.1.2012 s spletne strani: http://www.zzzs.si/zzzs/pao/izvajalci.nsf/o/0C38E1F23D 89C18FC125796F00173041.Search in Google Scholar

27. Zakonodaja Republike Slovenije. Zakon o duševnem zdravju Republike Slovenije. Pridobljeno 20.1.2012 s spletne strani: http:// zakonodaja.gov.si/rpsi/r07/predpis_ZAKO2157.html.Search in Google Scholar

28. Zavod za zdravstveno zavarovanje Republike Slovenije. Recept glasilo, zadnja verzija. Pridobljeno 20. 1. 2012 s spletne strani: http://www.zzzs.si/ZZZS/info/egradiva.nsf/0/2e6416e75fe33f0 5c125796c00492304/$FILE/Bilten%20Recept_%C5%A1t%20 1_20.12.2011.pdfSearch in Google Scholar

29. Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008; 7: 16.10.1186/1744-859X-7-16255307218755025Search in Google Scholar

30. Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand 2002; 106: 83-96.10.1034/j.1600-0447.2002.02120.x12121205Search in Google Scholar

31. Premuš A, Mrhar A. Interakcije med zdravili pri bolnikih na kirurškem oddelku Splošne bolnišnice Murska Sobota. Zdrav Var 2010; 49: 189-201.Search in Google Scholar

32. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-723.10.1093/schbul/sbj067263226216540702Search in Google Scholar

33. Obradović M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007; 6: 1979-1988.10.1111/j.1742-1241.2007.01431.x17997804Search in Google Scholar

34. Young W. The therapeutic window for methylprednisolone treatment of acute spinal cord injury: implications for cell injury mechanisms. Res Publ Assoc Res Nerv Ment Dis 1993; 71: 191-206.Search in Google Scholar

35. Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004; 7: 569-584.10.1111/j.1524-4733.2004.75008.x15367252Search in Google Scholar

36. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc 2006; 4: 10. 10.1186/1478-7547-4-10152520216737547Search in Google Scholar